TriangleNCT04644237 · OUTCOME
Time to Deterioration in European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) Scores
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- At baseline and at end of treatment 40-day follow-up visit
What was measured
The EORTC QLQ-C30 consists of 30 questions assessing global health-related quality of life, five aspects of subject functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), and six single-items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). All of the scales and single-item measures range in score from 0 to 100. Higher scores for functioning scales and global health status indicate a better level of functioning while higher scores on the symptom and single-item scales indicate a higher level of symptoms.
Analysis population: Full Analysis Set
Groups in this outcome
Trastuzumab Deruxtecan 5.4 mg/kg
Participants randomized to receive trastuzumab deruxtecan 5.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).
Trastuzumab Deruxtecan 6.4 mg/kg
Participants randomized to receive trastuzumab deruxtecan 6.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).
| Group | Source count |
|---|---|
| Trastuzumab Deruxtecan 5.4 mg/kg | 102 |
| Trastuzumab Deruxtecan 6.4 mg/kg | 50 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Trastuzumab Deruxtecan 5.4 mg/kg | 8.6 | Not reported | 4.9 | 11.4 | Not reported |
| Trastuzumab Deruxtecan 6.4 mg/kg | 9.3 | Not reported | 2.5 | NA | Not estimable due to insufficient number of participants with events |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 4.9
- upper Limit
- 11.4
- value
- 8.6
- comment
- Not estimable due to insufficient number of participants with events
- group Id
- OG001
- lower Limit
- 2.5
- upper Limit
- NA
- value
- 9.3
- denoms
- counts
- group Id
- OG000
- value
- 102
- group Id
- OG001
- value
- 50
- units
- Participants
- description
- The EORTC QLQ-C30 consists of 30 questions assessing global health-related quality of life, five aspects of subject functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), and six single-items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). All of the scales and single-item measures range in score from 0 to 100. Higher scores for functioning scales and global health status indicate a better level of functioning while higher scores on the symptom and single-item scales indicate a higher level of symptoms.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants randomized to receive trastuzumab deruxtecan 5.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).
- id
- OG000
- title
- Trastuzumab Deruxtecan 5.4 mg/kg
- description
- Participants randomized to receive trastuzumab deruxtecan 6.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).
- id
- OG001
- title
- Trastuzumab Deruxtecan 6.4 mg/kg
- param Type
- MEDIAN
- population Description
- Full Analysis Set
- reporting Status
- POSTED
- time Frame
- At baseline and at end of treatment 40-day follow-up visit
- title
- Time to Deterioration in European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) Scores
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice